Curcumin regulates colon cancer by inhibiting p-glycoprotein in In-situ cancerous colon perfusion rat model

Journal of Cancer Science and Therapy

Volumn 5, Issue 9, 2013, Pages 313-319

  Neerati, Prasad ^a   Sudhakar, Yakkanti A ^b   Kanwar, Jagat R ^c  

^a KAKATIYA UNIVERSITY   (India)

^b SRI INTERNATIONAL   (United States)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

Curcumin; Effective permeability; In situ colon perfusion; P glycoprotein; RP HPLC

Indexed keywords

CURCUMIN; GLYCOPROTEIN P INHIBITOR; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN; PROPRANOLOL; VERAPAMIL;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG PENETRATION; DRUG STABILITY; FOOD AND DRUG ADMINISTRATION; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTESTINE MUCOSA PERMEABILITY; MEMBRANE PERMEABILITY; NONHUMAN; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; RNA EXTRACTION; WESTERN BLOTTING;

EID: 84886803040     PISSN: None     EISSN: 19485956     Source Type: Journal    
DOI: 10.4172/1948-5956.1000221     Document Type: Article

References (47)

1. Anand P, Kunnumakkara AB, Sundaram C, Harikumar KB, Tharakan ST, et al. (2008) Cancer is a preventable disease that requires major lifestyle changes. Pharm Res 25: 2097-2116.
2. Kinzler KW, Vogelstein B (2002) Introduction: The genetic basis of human cancer. (2nd, illustrated, revised Ed.) Medical Pub Division, McGraw-Hill, New York.
3. Croce CM (2008) Oncogenes and cancer. N Engl J Med 358: 502-511.
4. Knudson AG (2001) Two genetic hits (more or less) to cancer. Nat Rev Cancer 1: 157-162.
5. Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, et al. (2004) Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 18: 2095-2107.
6. Veau C, Faivre L, Tardivel S, Soursac M, Banide H, et al. (2002) Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice. J Pharmacol Exp Ther 302: 742-750.
7. Gómez-Martínez A, García-Morales P, Carrato A, Castro-Galache MD, Soto JL, et al. (2007) Post-transcriptional regulation of P-glycoprotein expression in cancer cell lines. Mol Cancer Res 5: 641-653.
8. Schadendorf D, Herfordt R, Czarnetzki BM (1995) P-glycoprotein expression in primary and metastatic malignant melanoma. Br J Dermatol 132: 551-555.
9. Tokunaga Y, Hosogi H, Hoppou T, Nakagami M, Tokuka A, et al. (2001) Effects of MDR1/P-glycoprotein expression on prognosis in advanced colorectal cancer after surgery. Oncol Rep 8: 815-819.
10. Linn SC, Giaccone G (1995) MDR1/P-glycoprotein expression in colorectal cancer. Eur J Cancer 31A: 1291-1294.
11. Fillpits M, Suchomel RW, Dekan G, Stiglbauer W, Haider K, et al. (1997) Expression of the multidrug resistance-associated protein (MRP) gene in colorectal carcinomas. Br J Cancer 75: 208-212.
12. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767.
13. Linardi RL, Natalini CC (2006) Multi-drug resistance (MDR1) gene and P-glycoprotein influence on pharmacokinetic and pharmacodymanic of therapeutic drugs. Cienc Rural 36: 336-341.
14. Johnson SM, Gulhati P, Arrieta I, Wang X, Uchida T, et al. (2009) Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res 29: 3185-3190.
15. Katewa SD, Kapahi P (2011) Role of TOR signaling in aging and related biological processes in Drosophila melanogaster. Exp Gerontol 46: 382-390.
16. Lin CL, Lin JK (2008) Curcumin: a potential cancer chemo preventive agent through suppressing NF-kBsignaling. J Cancer Mol 4: 11-16.
17. Van Erk MJ, Teuling E, Staal YC, Huybers S, Van Bladeren PJ, et al. (2004) Time- and dose-dependent effects of curcumin on gene expression in human colon cancer cells. J Carcinog 3: 8.
18. Anand P, Thomas SG, Kunnumakkara AB, Sundaram C, Harikumar KB, et al. (2008) Biological activities of curcumin and its analogues (Congeners) made by man and Mother Nature. Biochem Pharmacol 76: 1590-1611.
19. Narisawa T, Fukaura Y, Hasebe M, Nomura S, Oshima S, et al. (1998) Prevention of N-methylnitrosourea-induced colon carcinogenesis in F344 rats by lycopene and tomato juice rich in lycopene. Jpn J Cancer Res 89: 1003-1008.
20. Jeong E, Huimin Lin, Ming (2000) In situ single-pass perfused rat colon model for absorption and metabolism. In: Methods in Pharmacology and Toxicology. Springer, Germany: 65-76.
21. Rabba AK, Si L, Xue K, Li M, Li G (2011) In Situ intestinal perfusion of irinotecan: application to P-gp mediated drug interaction and introduction of an improved HPLC assay. J Pharm Pharm Sci 14: 138-147.
22. Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Azarmi Y, Islambolchilar Z, et al. (2007) Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci 10: 368-379.
23. Song NN, Li QS, Liu CX (2006) Intestinal permeability of metformin using single-pass intestinal perfusion in rats. World J Gastroenterol 12: 4064-4070.
24. Zakeri-Milani P, Valizadeh H, Tajerzadeh H, Azarmi Y, Islambolchilar Z, et al. (2007) Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci 10: 368-379.
25. Sutton SC, Rinaldi MT, Vukovinsky KE (2001) Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model. AAPS PharmSci 3: E25.
26. Sutton SC, Rinaldi MT, Vukovinsky KE (2001) Comparison of the gravimetric, phenol red, and 14C-PEG-3350 methods to determine water absorption in the rat single-pass intestinal perfusion model. AAPS PharmSci 3: E25.
27. Miller DS, Bauer B, Hartz AM (2008) Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 60: 196-209.
28. Varma MV, Panchagnula R (2005) Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci 25: 445-453.
29. Amidon GL, Lennernäs H, Shah VP, Crison JR (1995) A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12: 413-420.
30. Varma MV, Kapoor N, Sarkar M, Panchagnula R (2004) Simultaneous determination of digoxin and permeability markers in rat in situ intestinal perfusion samples by RP-HPLC. J Chromatogr B Analyt Technol Biomed Life Sci 813: 347-352.
31. Varma MV, Panchagnula R (2005) Prediction of in vivo intestinal absorption enhancement on P-glycoprotein inhibition, from rat in situ permeability. J Pharm Sci 94: 1694-1704.
32. Salphati L, Childers K, Pan L, Tsutsui K, Takahashi L (2001) Evaluation of a single-pass intestinal-perfusion method in rat for the prediction of absorption in man. J Pharm Pharmacol 53: 1007-1013.
33. Bansal T, Mishra G, Jaggi M, Khar RK, Talegaonkar S (2009) Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Eur J Pharm Sci 36: 580-590.
34. Song NN, Li QS, Liu CX (2006) Intestinal permeability of metformin using single-pass intestinal perfusion in rats. World J Gastroenterol 12: 4064-4070.
35. Suitsui S, Pan L (2001) Evaluation of single pass intestinal perfusion in rat for the predictionof absorption in man. J Pharm Pharmacol 43: 1014-1021.
36. Lü Y, Yan Y, Wang XF (2004) Antiepileptic drug-induced multidrug resistance P-glycoprotein overexpression in astrocytes cultured from rat brains. Chin Med J (Engl) 117: 1682-1686.
37. Jeong E, Ming H (2000) Insitu single pass perfused rat intestinal model for absorption and metabolism. In methods in pharmacology and toxicology. Springer, Germany: 65-76.
38. Chiou WL, Barve A (1998) Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm Res 15: 1792-1795.
39. Miller DS, Bauer B, Hartz AM (2008) Modulation of P-glycoprotein at the blood-brain barrier: opportunities to improve central nervous system pharmacotherapy. Pharmacol Rev 60: 196-209.
40. Choi BH, Kim CG, Lim Y, Shin SY, Lee YH (2008) Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway. Cancer Lett 259: 111-118.
41. Um Y, Cho S, Woo HB, Kim YK, Kim H, et al. (2008) Synthesis of curcumin mimics with multidrug resistance reversal activities. Bioorg Med Chem 16: 3608-3615.
42. Baghdasaryan A, Claudel T, Kosters A, Gumhold J, Silbert D, et al. (2009) Curcumin improves sclerosing cholangitis in Mdr2-/- mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut 59: 521-530.
43. Limtrakul P, Chearwae W, Shukla S, Phisalphong C, Ambudkar SV (2007) Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin. Mol Cell Biochem 296: 85-95.
44. Singh DV, Godbole MM, Misra K (2013) A plausible explanation for enhanced bioavailability of P-gp substrates in presence of piperine: simulation for next generation of P-gp inhibitors. J Mol Model 19: 227-238.
45. Kanwar JR, Singh N, Kanwar RK (2011) Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma. Nanomedicine (Lond) 6: 701-714.
46. Shukla S, Zaher H, Hartz A, Bauer B, Ware JA, et al. (2009) Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res 26: 480-487.
47. Angelini A, Iezzi M, Di Febbo C, Di Ilio C, Cuccurullo F, et al. (2008) Reversal of P-glycoprotein-mediated multidrug resistance in human sarcoma MES-SA/ Dx-5 cells by nonsteroidal anti-inflammatory drugs. Oncol Rep 20: 731-735.